埃法维伦兹和多卢特格拉维尔对肠道微生物组和肠道屏障功能的比较
Yong-Xiang Huang1, Qin Tang1,2, Shi-Hua Fu3
1Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, No. 12 Jichang Road, Guangzhou 510405, China.
ACS omega
|June 16, 2025
概括
埃法维伦兹 (EFV) 和多卢特格拉维尔 (DTG) 抗逆转录病毒疗法可能会损害肠道健康. 与DTG相比,EFV显著减少了有益的肠道细菌,并损害了HIV患者和小鼠的肠道屏障.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 多卢特格拉维尔 (DTG) 正在取代 efavirenz (EFV) 在一线抗逆转录病毒疗法 (cART) 中,因为耐受性更好.
- 基于EFV和DTG的cART的代谢和神经精神方面的副作用背后的机制尚不清楚.
研究的目的:
- 调查基于EFV和DTG的cART对肠道微生物群和肠道屏障完整性的影响.
- 为了比较EFV和DTG对HIV-1感染个体和小鼠模型中的肠道健康的影响.
主要方法:
- 基于EFV与DTG的cART对HIV-1患者的乳酸菌丰度和可溶性CD14水平的分析.
- 在接受EFV,DTG或不接受治疗的小鼠中,评估肠道形态,杯状细胞数,ZO-1表达和肠道屏障完整性.
主要成果:
- 基于EFV的cART治疗的HIV-1患者与基于DTG的cART治疗患者相比,Lactobacillus的减少和可溶性CD14的增加.
- 在小鼠中,EFV治疗导致肠道密室的破坏,杯状细胞的损失,ZO-1表达的减少和肠道屏障完整性的损害.
- 在EFV治疗的小鼠中观察到乳酸菌的显著减少.
结论:
- EFV和DTG可能会直接诱导肠道失调,并损害肠道屏障功能.
- 针对肠道健康可能是减轻EFV和DTG在HIV治疗中的不良影响的策略.
更多相关视频
相关概念视频
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
207
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
207
Surface Membrane Barriers
1.5K
The skin and mucous membranes serve as the primary line of defense against pathogens by providing both physical and chemical protection. These barriers are essential in preventing the entry and establishment of microbes, thereby maintaining the integrity of the host.
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
1.5K
Drug Absorption: Factors Affecting GI Absorption
4.8K
The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
4.8K
Antimicrobial Effectiveness
175
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
175
Mucosal Barrier of the Stomach
850
The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
850
Drugs for Treatment of Diarrhea-Predominant IBS
315
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
315


